Colesterol HDL y enfermedad cardiovascular en una población con hipertensión y diabetes mellitus tipo 2. Estudio RICARHD

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9.

Shepherd, 1995, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group, N Engl J Med, 333, 1301, 10.1056/NEJM199511163332001

Downs, 1998, Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS (Air Force/Texas Coronary Atherosclerosis Prevention Study), JAMA, 279, 1615, 10.1001/jama.279.20.1615

2002, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial, Lancet, 360, 7, 10.1016/S0140-6736(02)09327-3

Collins, 2003, MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial, Lancet, 361, 2005, 10.1016/S0140-6736(03)13636-7

Colhoun, 2004, Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial, Lancet, 364, 685, 10.1016/S0140-6736(04)16895-5

Shah, 2001, Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I, Circulation, 104, 2376, 10.1161/hc4401.098467

Gordon, 1977, High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study, Am J Med, 62, 707, 10.1016/0002-9343(77)90874-9

Assmann, 1996, High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport, Atherosclerosis, 124, S11, 10.1016/0021-9150(96)05852-2

Gordon, 1989, High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies, Circulation, 79, 8, 10.1161/01.CIR.79.1.8

Carmena, 2005, Type 2 diabetes, dyslipidemia, and vascular risk: rationale and evidence for correcting the lipid imbalance, Am Heart J, 150, 859, 10.1016/j.ahj.2005.04.027

Cea-Calvo, 2006, Target organ damage and cardiovascular complications in patients with hypertension and type 2 diabetes in Spain: a cross-sectional study, Cardiovasc Diabetol, 5, 23, 10.1186/1475-2840-5-23

Casale, 1985, Electrocardiographic detection of left ventricular hypertrophy: development and prospective validation of improved criteria, J Am Coll Cardiol, 6, 572, 10.1016/S0735-1097(85)80115-7

Sokolow, 1949, Ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads, Am Heart J, 37, 161, 10.1016/0002-8703(49)90562-1

Levey, 2003, National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification, Ann Intern Med, 139, 137, 10.7326/0003-4819-139-2-200307150-00013

Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J. 2007;28:2375-414.

Sacks, 2000, Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project, Circulation, 102, 1893, 10.1161/01.CIR.102.16.1893

Barter, 2007, HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events, N Engl J Med, 357, 1301, 10.1056/NEJMoa064278

Brown, 2006, Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials, Curr Opin Lipidol, 17, 631, 10.1097/MOL.0b013e32800ff750

Turner, 1998, Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23), BMJ, 316, 823, 10.1136/bmj.316.7134.823

Bansal, 2007, Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women, JAMA, 298, 309, 10.1001/jama.298.3.309

Norderstgaard, 2007, Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease and death in men and women, JAMA, 298, 299, 10.1001/jama.298.3.299

Packard, 2000, The role of small, dense low density lipoprotein (LDL): a new look, Int J Cardiol, 74, S17, 10.1016/S0167-5273(99)00107-2

Canner, 2005, Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project), Am J Cardiol, 95, 254, 10.1016/j.amjcard.2004.09.013

Niacin plus statin to prevent vascular events. AIM-HIGH. Clinicaltrials. gov, NCT00120289 [Consultado: 29-julio-2008] Disponible en: http://www.clinicaltrials.gov/ct2/show/NCT00120289?term=aim-high&rank=1

Treatment of HDL to reduce the Incidence of vascular events HPS2-THRIVE. Clinicaltrials.gov, NCT00461630. [Consultado: 29-julio-2008] Disponible en: http://www.clinicaltrials.gov/ct/show/NCT00461630?order=1